Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Immune checkpoint inhibitors
9 evidence topics · 6 sources
FDA-approved indication: pembrolizumab as a single agent
Recommended dosage in BCG-unresponsive high-risk NMIBC
KEYNOTE-057 Cohort A: design and population
KEYNOTE-057 Cohort A: efficacy in the prescribing information
| Endpoint | Pembrolizumab 200 mg every 3 weeks |
|---|---|
| Participants | “n=96” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Duration of response ≥12 months, % (n) | “46% (18)” |
| Basis of duration of response | “Based on patients (n=39) that achieved a complete response” |
KEYNOTE-057 Cohort A: primary publication
“In cohort A of the trial, adults aged 18 years or older with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, with an Eastern Cooperative Oncology Group performance status of 0-2, and who were ineligible for or declined radical cystectomy were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was clinical complete response rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assessed by cystoscopy and urine cytology approximately 3 months after the first dose of study drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 36·4 months (IQR 32·0-40·7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“39 (41%; 95% CI 30·7-51·1) of 96 patients with BCG-unresponsive carcinoma in situ of the bladder with or without papillary tumours had a complete response at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-057 Cohort B: papillary-only disease
“Cohort B eligible patients were aged 18 years and older, had an Eastern Cooperative Oncology Group performance status of 0-2, and had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-grade Ta or any-grade T1) without carcinoma in situ.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Primary endpoint was 12-month disease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assessed by cystoscopy, cytology, and central pathology and radiology review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 12-month disease-free survival was 43·5% (95% CI 34·9-51·9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events occurred in 97 (73%) of 132 patients; 19 (14%) had a grade 3 or 4 treatment-related adverse event; the most common grade 3 or 4 treatment-related adverse events were colitis (in three [2%] patients) and diarrhoea (in two [2%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings will need to be confirmed in a randomised controlled trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety in KEYNOTE-057
FDA advisory committee review of KEYNOTE-057
“In KEYNOTE-057, the CRR at first disease assessment was 41% (95% CI: 31%, 51%) and median DOR was 16.2 months; 46% of responders remaining in response for at least 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The committee voted 9–4 in favor of a favorable benefit-risk profile for these patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote